Sign in
CompletedNo phase

Alcoholic Hepatitis Network Observational Study

Key facts

Who runs it
Indiana University
Where
Boston, Cleveland, Dallas, Indianapolis, Louisville, Pittsburgh, Richmond, Rochester, and Worcester, United StatesSee the 9 sites
Trial code
Status
Completed
People taking part
1,133 people enrolled
Started
17 Apr 2019
Ended
21 Jun 2024
Type of study
Observational, 3 groups
Record updated
14 February 2025

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • A clinical diagnosis of alcoholic hepatitis as defined by the NIAAA pan-consortia for AH:; Onset of jaundice (defined as serum total bilirubin >3 mg/dL) within the prior 8 weeks to screening visit; Regular consumption of alcohol with an intake of > 40 gm daily or >280gm weekly on average for women and > 60 gm daily or >420gm weekly on average for men for 6 months or more, with less than 8 weeks of abstinence before onset of jaundice; AST > 50 IU/l; AST:ALT > 1.5 and both values < 400 IU/l; and/or histological evidence of AH*
  • Serum total bilirubin >3 mg/dL
  • Subject or guardian ability to understand and willingness to provide written consent
  • Age greater or equal to 21 years
  • Re-enrolment of an alcoholic hepatitis donor is permissible up to 4 times if the donor presents with a new episode of alcoholic hepatitis 24 weeks or longer after the most recent enrolment in the study
  • AUDIT-C scores of <4 for men and <3 for women (signifying no alcohol misuse)
  • Abstinent (consumption of less than one standard drink/week) during the 6 months prior to enrolment
  • Ability to understand and willingness to provide written consent
  • Age greater or equal to 21 years

Who cannot take part

  • Received liver transplant
  • If liver stiffness has been assessed within the prior 90 days, then stiffness suggesting fibrosis of F1 or greater is excluded. For Fibroscan, this is a fibrosis score >7.0 kPa
  • Received liver transplant
  • Presence of diabetes (requiring treatment with oral agents or insulin)
  • Significant heart disease (prior history of heart disease, other than hypertension)
  • Received liver transplant
  • Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, HIV, or stage 1 (one lesion <2 cm) HCC is not exclusion to participation)
  • Based on the judgment of the investigator, subject is not capable of understanding or complying with the study requirements; CONTROLS: Heavy drinkers without significant liver disease Inclusion criteria
  • History of chronic alcohol consumption sufficient to cause liver damage. Generally, this is considered to be >40 g/day or >280g/week on average for women and >60 g/day or >420 g/week on average for men, for 6 months or more. Judgement about chronic alcohol consumption will be made by the site investigator
  • Chronic lung disease (requiring chronic treatment)
  • Immune related conditions (such as Crohn's disease, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, severe psoriasis, etc.)
  • Known infection with HIV
  • Presumed infection, or use of antibiotics or other medications (e.g., corticosteroids) that would affect immune function, within the past 14 days
  • Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment
  • Past evidence of alcoholic liver disease, defined as a bilirubin > 2.0 mg/dL, an AST > 1.5 ULN, and any hospital admission for liver disease, or the presence of esophageal varices or ascites (at any time in the past)
  • Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, or HIV is not exclusion to participation.); *Individuals with a diagnosis of Gilbert's can have total bilirubin up to 3.0 mg/dL and still be eligible for participation
  • Any of the following laboratory abnormalities within 90 days prior to signing the consent; Total bilirubin: >ULN*; INR: > 1.4; Healthy Controls
  • Clinical history or laboratory evidence of liver disease including alcoholic liver disease, NAFLD, hemochromatosis, alcoholic hepatitis, autoimmune liver disease, Wilson disease, hepatitis C, or hepatitis B
  • Any of the following laboratory abnormalities within 90 days prior to signing the consent; Hemoglobin: <10 g/dL; Conjugated bilirubin: > ULN; INR: > 1.4; AST: >40 IU/mL; ALT: >40 IU/mL
  • Age greater or equal to 21 years
  • Pregnant or breast feeding
  • Subject or guardian ability to understand and willingness to provide written consent
  • Alcohol intake at less than 40 g/day or 280g/week on average for women and 60 g/day or 420 g/week on average for men for longer than the past 28 days
  • Pregnant or breast feeding
  • BMI>35
  • Pregnant or breast feeding
  • Based on the judgment of the investigator, subject is not capable of complying with the study requirements

Other criteria

  • CASES: Heavy drinkers with alcoholic hepatitis

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United States
  • Cleveland ClinicCleveland, United States
  • University of Texas Southwestern Medical SchoolDallas, United States
  • IU School of MedicineIndianapolis, United States
  • University of LouisvilleLouisville, United States
  • University of PittsburghPittsburgh, United States
  • Virginia Commonwealth UniversityRichmond, United States
  • Mayo ClinicRochester, United States
  • University of MassachusettsWorcester, United States

About the trial

What the trial wants to find out

The purpose of this research study is to create a clinical database and bio-repository. To do this, we will obtain blood, urine, saliva, and stool samples (e.g., biological samples) and personal health information from you to use in future research studies related to alcoholic hepatitis or other diseases. Part of your blood sample will be used to extract your DNA. DNA is the genetic material that gives us unique characteristics. We are doing this research study because we are trying to find out more about how and why illnesses related to alcoholic hepatitis or other diseases occur in people. To do this, we will study the biological samples and personal health information from healthy and sick people.

Read full original descriptionShow less

A "biological sample" is usually blood, but can be any body fluid. "Personal Health Information" includes such items as your name, age, gender, race, and/or your medical information. It can also include data from measurements and tests that you had while participating in another research study or that were done during the course of your regular medical care or doctor visits.

The 3 groups in the trial

  • Cases

    Heavy drinkers with alcoholic hepatitis

  • Controls

    Heavy drinkers without significant liver disease

  • Donor

    Healthy non-drinkers

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
14 February 2025